These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2540920)

  • 1. Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade.
    Ranger S; Talajic M; Lemery R; Roy D; Nattel S
    Circulation; 1989 May; 79(5):1000-6. PubMed ID: 2540920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts.
    Coromilas J; Saltman AE; Waldecker B; Dillon SM; Wit AL
    Circulation; 1995 Apr; 91(8):2245-63. PubMed ID: 7697855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits.
    Restivo M; Yin H; Caref EB; Patel AI; Ndrepepa G; Avitable MJ; Assadi MA; Isber N; el-Sherif N
    Circulation; 1995 Feb; 91(4):1236-46. PubMed ID: 7850964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical.
    Heath BM; Cui Y; Worton S; Lawton B; Ward G; Ballini E; Doe CP; Ellis C; Patel BA; McMahon NC
    J Pharmacol Toxicol Methods; 2011; 63(3):258-68. PubMed ID: 21194571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans.
    Ranger S; Talajic M; Lemery R; Roy D; Villemaire C; Nattel S
    Circulation; 1991 Jun; 83(6):1987-94. PubMed ID: 2040051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent.
    Sadanaga T; Ogawa S
    J Am Coll Cardiol; 1994 May; 23(6):1378-81. PubMed ID: 8176096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of flecainide on exercise hemodynamics and electrocardiography in patients without structural heart disease.
    Wang JA; Lau CP; Tai YT; Wu BZ
    Clin Cardiol; 1995 Mar; 18(3):140-4. PubMed ID: 7743684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Routine Exercise Testing to Detect Rate-Related QRS Widening in Patients Without Structural Heart Disease on Class Ic Antiarrhythmic Agents (Flecainide and Propafenone).
    Vallurupalli S; Pothineni NV; Deshmukh A; Paydak H
    Am J Cardiol; 2015 Sep; 116(5):730-2. PubMed ID: 26100588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of an anesthetized dog model of transient cardiac ischemia and rapid pacing: a pilot study for preclinical assessment of the potential for proarrhythmic risk of novel drug candidates.
    Damiano BP; van der Linde HJ; Van Deuren B; Somers Y; Lubomirski M; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2015; 72():72-84. PubMed ID: 25450838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant arrhythmias and acute myocardial ischemia: interaction between flecainide and the autonomic nervous system.
    Stramba-Badiale M; Lazzarotti M; Facchini M; Schwartz PJ
    Am Heart J; 1994 Nov; 128(5):973-82. PubMed ID: 7524295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
    Katritsis D; Rowland E; O'Nunain S; Shakespeare CF; Poloniecki J; Camm AJ
    Eur Heart J; 1995 Dec; 16(12):1930-5. PubMed ID: 8682029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use dependence of amiodarone during the sinus tachycardia of exercise in coronary artery disease.
    Cascio WE; Woelfel A; Knisley SB; Buchanan JW; Foster JR; Gettes LS
    Am J Cardiol; 1988 May; 61(13):1042-5. PubMed ID: 3364359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
    Lu HR; Rohrbacher J; Vlaminckx E; Van Ammel K; Yan GX; Gallacher DJ
    Br J Pharmacol; 2010 May; 160(1):60-76. PubMed ID: 20331615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans.
    Kidwell GA; Greenspon AJ; Greenberg RM; Volosin KJ
    Circulation; 1993 Jan; 87(1):118-25. PubMed ID: 8418998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue.
    Wang Z; Fermini B; Nattel S
    J Pharmacol Exp Ther; 1993 Nov; 267(2):575-81. PubMed ID: 8246130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments.
    Starmer CF; Lastra AA; Nesterenko VV; Grant AO
    Circulation; 1991 Sep; 84(3):1364-77. PubMed ID: 1653123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate in dogs.
    Salerno DM; Murakami MM; Johnston RB; Keyler DE; Pentel PR
    Am J Emerg Med; 1995 May; 13(3):285-93. PubMed ID: 7755819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proarrhythmic and antiarrhythmic effects of flecainide on nonsustained reentry around the canine atrial tricuspid ring in vitro.
    Frame LH; Rhee EK; Fei H; Luchetti W
    Pacing Clin Electrophysiol; 1991 Nov; 14(11 Pt 2):1728-34. PubMed ID: 1721165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial (ESVEM) Investigators.
    Freedman RA; Steinberg JS
    J Am Coll Cardiol; 1991 Apr; 17(5):1017-25. PubMed ID: 1848871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects.
    Sihm I; Hansen FA; Rasmussen J; Pedersen AK; Thygesen K
    Eur Heart J; 1990 Feb; 11(2):145-8. PubMed ID: 2107078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.